The aim of this study is to assess the R0 resection rate of tislelizumab combined with
Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally
Translational therapy refers to methods such as chemotherapy, radiotherapy, immunotherapy,
targeted and combined therapy to shrink tumors, reduce tumor biological behavior, and achieve
secondary resection. The success rate of transformation depends on the objective response
rate of the treatment method (Objective response rate, ORR). The latest review showed that
132 patients with unresectable ICC had undergone chemotherapy, chemoembolization,
radiotherapy embolization or combination therapy, and 27 patients received downgrade
resection. The research of our group using PD-1 antibody combined with lenvatinib and Gemox
chemotherapy in the first-line treatment of unresectable advanced cholangiocarcinoma
(NCT03951597, 2020ESMO, 2021ASCO) showed that the ORR was 80% and the disease control rate
(DCR) It reached 93.3% (28/30), of which 3 cases underwent successful radical resection after
downstage. These data suggest that PD1 monoclonal antibody combined with lenvatinib and Gemox
chemotherapy may be an ideal conversion therapy for patients with potentially resectable
advanced biliary system tumors, but there is currently no evidence-based basis.
This study explores the efficacy and safety of PD1 monoclonal antibody combined with
Lenvatinib and Gemox chemotherapy in potentially resectable advanced BTC conversion therapy.
It has certain clinical significance in order to increase the R0 surgical resection rate of
BTC patients and improve patient survival.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.